Two Revvity CE marked tests are recommended in latest version of NICE guidance “PLGF-based testing to help diagnose suspected preterm pre-eclampsia” for UK healthcare providers
Image: Revvity
We are happy to inform you that our DELFIA® Xpress PlGF 1-2-3 (CE-IVD) and DELFIA® Xpress sFlt-1/PlGF 1-2-3 ratio (CE-IVD) have been included in an updated diagnostic guidance issued by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to help diagnose suspected preterm pre-eclampsia.
NICE guidelines are evidence-based recommendations for health and care in the UK. Even though UK-based, the NICE recommendations are appreciated and followed globally. Per its latest guidance on helping diagnose suspected preterm pre-eclampsia the DELFIA Xpress PlGF 1-2-3 and DELFIA Xpress sFlt-1/PlGF 1-2-3 ratio are recommended for use, along with a standard clinical assessment, to confirm suspected preterm pre-eclampsia in women from 20 weeks of pregnancy onwards.
We are encouraged that NICE has expanded its list of approved solutions for the diagnosis of this condition, and are confident that in doing so, there will be better health outcomes for mothers and babies.
Revvity is the only test developer to offer two different options recommended for helping diagnose pre-eclampsia – the DELFIA Xpress PlGF 1-2-3 kit, that may be used alone as s single marker, and the DELFIA Xpress sFlt-1 kit, that may be used together with the PlGF 1-2-3 kit as sFlt-1/PlGF ratio. Revvity also offers the DELFIA® Xpress random access platform for prenatal screening, which is used to process tests from both kits.
To learn more about the CE marked test kits included in this NICE guidance, along with other solutions for pre-eclampsia screening and management, visit this webpage.
Source: Company Press Release